The Drug Development Unit aims to seamlessly integrate preclinical drug discovery, proof-of-principle phase I trials and tumour-specific evaluation of novel agents. It is a conduit for the two-way communication between laboratory and clinical teams that is so essential for successful modern drug development.
The unit includes The Oak Foundation Drug Development Centre – housed within The Royal Marsden at the Sutton site and specifically designed for phase I clinical trials. Opened in February 2005, the centre provides 10 inpatient beds, five treatment chairs and two outpatient suites, and allows researchers to enter almost 300 patients onto phase I trials each year. This makes the unit one of the largest of its kind in the world.
On 16 April, the ICR and the Experimental Cancer Medicine Centres (ECMC) will jointly present an immunohistochemistry workshop on emerging technologies and application of mmunohistochemistry (IHC) in clinical research. The workshop is in Sutton and is aimed at researchers and clinicians working on IHC and PhD students.
Many of these trials at the Drug Development Unit investigate ‘molecularly targeted treatments’, where treatments are matched to the particular molecular features of a patient’s tumour.
Staff at the unit molecularly characterise patients entering phase I studies by detecting mutations in tumours and in the blood.
Patients are then placed onto trials of agents targeting their mutations. Selecting patients for early-phase clinical trials in this way increases the likelihood that they will benefit from their treatment.
The eventual goal is fully personalised medicine, with drugs exploiting the specific weaknesses of a tumour at a particular point in time.